Abstract
Adenosine (Ado) and some non-adenosine (non-Ado) nucleosides including inosine (Ino), guanosine (Guo) and uridine (Urd) are modulatory molecules in the central nervous system (CNS), regulating different physiological and pathophysiological processes in the brain such as sleep and epilepsy. Indeed, different drugs effective on adenosinergic system (e.g., Ado metabolism inhibitors, agonists and antagonists of Ado receptors) are being used in drug development for the treatment of epileptic disorders. Although (i) endogenous Ino, Guo and Urd showed anticonvulsant/antiepileptic effects (e.g., in quinolinic acid - induced seizures and in different epilepsy models such as hippocampal kindling models), and (ii) there is a need to generate new and more effective antiepileptic drugs for the treatment of drug-resistant epilepsies, our knowledge about antiepileptic influence of non-Ado nucleosides is far from complete. Thus, in this review article, we give a short summary of anticonvulsant/antiepileptic effects and mechanisms evoked by Ino, Guo, and Urd. Finally, we discuss some non-Ado nucleoside derivatives and their structures, which may be candidates as potential antiepileptic agents.
Mini-Reviews in Medicinal Chemistry
Title:Non-adenosine Nucleoside Inosine, Guanosine and Uridine as Promising Antiepileptic Drugs: a Summary of Current Literature
Volume: 14 Issue: 13
Author(s): Zsolt Kovacs, Katalin A. Kekesi, Gabor Juhasz, Janos Barna, Laszlo Heja, Renata Lakatos and Arpad Dobolyi
Affiliation:
Keywords: Epilepsy, guanosine, inosine, uridine.
Abstract: Adenosine (Ado) and some non-adenosine (non-Ado) nucleosides including inosine (Ino), guanosine (Guo) and uridine (Urd) are modulatory molecules in the central nervous system (CNS), regulating different physiological and pathophysiological processes in the brain such as sleep and epilepsy. Indeed, different drugs effective on adenosinergic system (e.g., Ado metabolism inhibitors, agonists and antagonists of Ado receptors) are being used in drug development for the treatment of epileptic disorders. Although (i) endogenous Ino, Guo and Urd showed anticonvulsant/antiepileptic effects (e.g., in quinolinic acid - induced seizures and in different epilepsy models such as hippocampal kindling models), and (ii) there is a need to generate new and more effective antiepileptic drugs for the treatment of drug-resistant epilepsies, our knowledge about antiepileptic influence of non-Ado nucleosides is far from complete. Thus, in this review article, we give a short summary of anticonvulsant/antiepileptic effects and mechanisms evoked by Ino, Guo, and Urd. Finally, we discuss some non-Ado nucleoside derivatives and their structures, which may be candidates as potential antiepileptic agents.
Export Options
About this article
Cite this article as:
Kovacs Zsolt, Kekesi A. Katalin, Juhasz Gabor, Barna Janos, Heja Laszlo, Lakatos Renata and Dobolyi Arpad, Non-adenosine Nucleoside Inosine, Guanosine and Uridine as Promising Antiepileptic Drugs: a Summary of Current Literature, Mini-Reviews in Medicinal Chemistry 2014; 14 (13) . https://dx.doi.org/10.2174/1389557514666141107120226
DOI https://dx.doi.org/10.2174/1389557514666141107120226 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Canonical Wnt Signaling Pathway in Autism
CNS & Neurological Disorders - Drug Targets Editorial
Current Medical Imaging Anticonvulsant and Antitubercular Activities of 6-Phenyl/Biphenyl-4-yl-2- [2-(pyridin-2-ylamino)-ethyl]- and 6-(Biphenyl-4yl)-2-(2N-subtituted amin- 1-yl)-ethyl derivatives of 4,5-dihydropyridazin-3(2H)-one
Letters in Drug Design & Discovery Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Gender Medicine and Pharmacoeconomics: A Narrative Review of the International Literature of the Last 5 Years. A Revision of Evidences about the Relationship Between Gender and Economic Consumption in Health
Current Pharmaceutical Design Relationship Between Polymerase Gamma (POLG) Polymorphisms and Antiretroviral Therapy-Induced Lipodystrophy in HIV-1 Infected Patients: A Case-Control Study
Current HIV Research Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence
Current Neuropharmacology REM sleep and its Loss-Associated Epigenetic Regulation with Reference to Noradrenaline in Particular
Current Neuropharmacology Nitric Oxide Induced Damage and Preventive Effect of Curcumin and Quercetin on Buffalo Brain Cystatin
Current Proteomics Patents on Non-Viral Mediated Gene Delivery
Recent Patents on DNA & Gene Sequences Past, Present and Future of Antiepileptic Drug Therapy - Finding a Place for Heterocyclics
Mini-Reviews in Medicinal Chemistry Damaged Proteins Bearing L-Isoaspartyl Residues and Aging: A Dynamic Equilibrium Between Generation of Isomerized Forms and Repair by PIMT
Current Aging Science Down Regulated Expression of Claudin-1 and Claudin-5 and Up Regulation of β-Catenin: Association with Human Glioma Progression
CNS & Neurological Disorders - Drug Targets One Pot Synthesis, Characterization, DFT Studies and AIM Analyses of Ethyl-1-aryl-1H-tetrazole-5-carboxylate
Letters in Organic Chemistry Meningitis Due to Cryptococcus neoformans: Treatment with Posaconazole
Current HIV Research Role of Positron Emission Tomography for Central Nervous System Involvement in Systemic Autoimmune Diseases: Status and Perspectives
Current Medicinal Chemistry L-Type Calcium Channels
Current Pharmaceutical Design Adenosine Receptor Ligands-Recent Developments Part I. Agonists
Current Medicinal Chemistry Integrating Virtual Screening Methods to the Quest for Novel Membrane Protein Ligands
Current Medicinal Chemistry - Central Nervous System Agents